•  
  •  
  •  
  •  

2023-09-22 20:20:35

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Regency Ceramics Ltd kickstarts its revival, commences product deliveries in Chennai
  • Cigniti Technologies Recognized as a Leader in Everest Group's Quality Engineering Services PEAK Matrix® Assessment 2023
  • SBI raises Rs. 10,000 crores through 4th infrastructure bond issue
  • Technical Wrap - Sep 22, 2023 - HDFC Securities
  • Federal Bank Hosted a Cricket Extravaganza: ICC Men's Cricket World Cup Trophy Tour Arrived with a Bang!

Keywords Selected:  INE935A01035

Stock Report

  • Glenmark Pharmaceuticals Ltd to sell stake in Glenmark Life Sciences Ltd to Nirma Ltd
  • Glenmark Pharmaceuticals Inc., USA Reaches Antitrust Settlement with DOJ
  • Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%
  • Glenmark Pharmaceuticals receives ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg
  • Glenmark Pharmaceuticals Ltd. becomes a part of the Science Based Targets Initiative, sets GHG emission targets for FY2035
  • Glenmark Pharmaceuticals receives ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam
  • Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg
  • Glenmark receives acceptance from U.S. FDA for Phase 1/2, first-in-human clinical study of GRC 54276
  • Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP
  • Glenmark and Cediprof announces Exclusive Distribution agreement in the United States
  • Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg
  • Glenmark Pharmaceuticals Ltd updates on Baddi facility
  • Glenmark launches AKYNZEO® I.V. in India
  • Glenmark Pharmaceuticals Ltd to divest select brands to Eris Oaknet Healthcare Pvt Ltd
  • Glenmark Pharmaceuticals launches Bumetanide Injection
  • Glenmark launches Triple FDC of Teneligliptin + Pioglitazone + Metformin for Adults with Type 2 Diabetes & High Insulin Resistance
  • Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg
  • Glenmark Pharmaceuticals Ltd to divest its Cardiac brand, Razel®, in India and Nepal
  • Glenmark Pharmaceuticals Ltd gets US FDA warning letter for Goa manufacturing facility
  • Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg
  • Glenmark Pharmaceuticals receives ANDA approval for Sodium Phenylbutyrate Tablets USP, 500 mg
  • Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US
  • Glenmark Pharmaceuticals Limited Update on Baddi Facility
  • Glenmark launches Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities

Latest Post

  • Regency Ceramics Ltd kickstarts its revival, commences product deliveries in Chennai
  • Cigniti Technologies Recognized as a Leader in Everest Group's Quality Engineering Services PEAK Matrix® Assessment 2023
  • SBI raises Rs. 10,000 crores through 4th infrastructure bond issue
  • Technical Wrap - Sep 22, 2023 - HDFC Securities
  • Federal Bank Hosted a Cricket Extravaganza: ICC Men's Cricket World Cup Trophy Tour Arrived with a Bang!


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2022